GPR171 and neoplasm: In MC38 colon cancer, the treatment of GPR171 antagonist right after MC38 inoculation significantly retarded tumor growth; as a result, 18 days after tumor inoculation, tumor weight in the GPR171 antagonist-treated group was only about 40% of the control group (Fig. 5a).